Fundraising FoxAbpro
OTC: ABPOWoburn, US · Delaware corporation · 1 known investors
Find your way into Abpro
Sign up to see every warm intro you have to Abpro
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Abpro team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Abpro develops multispecific antibody therapeutics using proprietary discovery and engineering platforms, with lead programs targeting immuno-oncology, ophthalmology, and infectious disease; its advanced TetraBi antibody candidates ABP-102 (a T-cell engager for HER2+ solid tumors in partnership with Celltrion) and ABP-201 (targeting vascular disease in the eye through a territorial partnership with Abpro Bio) are designed to provide improved efficacy and safety profiles compared to existing treatments.
Founders & leadership
Board
Investors · 1
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$42.4M disclosed across 4 rounds · 2016–2022
▶$2MraisedApr 2022 · 1 investors · BiotechnologyRule 506(b)
- Mark TangDirector
- Ian ChanExecutive Officer, Director
- Miles SukDirector
- Eugene ChanExecutive Officer, Director
- Robert LangerDirector
- Offering amount
- $80M
- Amount sold
- $2M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18MraisedJan 2020 · 1 investors · BiotechnologyRule 506(b)
- Ian ChanExecutive Officer, Director
- Eugene ChanExecutive Officer, Director
- Miles J. SukDirector
- Robert LangerDirector
- Mark TangDirector
- Offering amount
- $40M
- Amount sold
- $18M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedApr 2017 · 1 investors · BiotechnologyRule 506(b)
- Ian ChanExecutive Officer, Director
- Benjamin HaDirector
- Thomas WengDirector
- Feng YeDirector
- Adam S. MostafaExecutive Officer
- Shengxin QinDirector
- Eugene ChanDirector
- Offering amount
- $30M
- Amount sold
- $10M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.4MraisedMar 2016 · 7 investors · BiotechnologyRule 506(b)
- Eugene ChanDirector
- Benjamin HaDirector
- Ian ChanExecutive Officer, Director
- Shengxin QinDirector
- Thomas WengDirector
- Kevin ComerfordExecutive Officer
- Offering amount
- $20M
- Amount sold
- $12.4M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Abpro do?
- Abpro develops multispecific antibody therapeutics using proprietary discovery and engineering platforms, with lead programs targeting immuno-oncology, ophthalmology, and infectious disease; its advanced TetraBi antibody candidates ABP-102 (a T-cell engager for HER2+ solid tumors in partnership with Celltrion) and ABP-201 (targeting vascular disease in the eye through a territorial partnership with Abpro Bio) are designed to provide improved efficacy and safety profiles compared to existing treatments.
- Who founded Abpro?
- Abpro was founded by Eugene Chan, Ian Chan.
- Who are Abpro's investors?
- Abpro's investors include Yorkville Advisors.
- How much funding has Abpro raised?
- Abpro has disclosed $42.4M raised across 4 rounds.
- Where is Abpro headquartered?
- Abpro is headquartered in Woburn, US.